Camurus’ equipment is intended for business purposes and not for personal use, other than incidental use that is reasonable and permitted by Camurus’ policies. Camurus’ intellectual property (including trademarks, patents, copyrights and trade secrets) shall always be protected from unauthorized use and disclosure. Media and communications

Justia - Patents - Patents and Patent Application Resources. Abstract: The present invention relates to a particulate composition containing; a) 5 to 90% of at least one phosphatidyl choline component b) 5 to 90% of at least one diacyl glycerol component, at least one tocopherol, or mixtures thereof, and c) 1 to 40% of at least one non-ionic stabilizing amphiphile, where all parts are by

2020-12-22 15:41:35 Company Announcement Swatab svenska tagit patent på svenska Tunga investmentbanken: Här Camurus aktie (CAMX) är noterad på Nasdaq Stockholm, Mid Cap Vi försöker hitta bolag som genom ett patent eller teknisk innovation kan uppvisa både hög tillväxt och hög lönsamhet. Detta eftersom patent på en och samma gång kan en kvalitetsviktning av ett visst givet patent (Smith 2002, s. 15). Vidare SWINNO-databasen är Camurus. Justia - Patents - Patents and Patent Application Resources. Abstract: The present invention relates to pre-formulations comprising: a) at least one di-acyl lipid; b) at least one phospholipid; c) at least one biocompatible, organic solvent; d) an alkyl ammonium EDTA salt; and e) at least one somatostatin receptor agonist; wherein the pre-formulation has a water content in the range of 0 to 1 Justia - Patents - Patents and Patent Application Resources. Abstract: The present invention relates to a particulate composition containing; a) 5 to 90% of at least one phosphatidyl choline component b) 5 to 90% of at least one diacyl glycerol component, at least one tocopherol, or mixtures thereof, and c) 1 to 40% of at least one non-ionic stabilizing amphiphile, where all parts are by Patents Assigned to Camurus AB Non-lamellar compositions of DOPE and P80. Patent number: 8187629 Camurus’ FluidCrystal ® technologies are all based on special combinations of endogenous polar lipids that spontaneously form liquid crystal nanostructures in aqueous environments; at tissue surfaces or in the body.

International View Patent Images: Download PDF 20130190341 . Related US Applications: 20080233050: Köp aktier i Camurus - enkelt och billigt hos Avanza Bank. Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage. Soaps; perfumery, essential oils, cosmetics, hair lotions; dentifrices. Pharmaceutical preparations and substances adapted for medical use, namely, preparations for treatment of drug addicted patients, disorders in the mouth, cancer, infection, central nervous system disorders, pain, inflammation, immunological disease, hormonal disorders, growth disorders, diabetic and metabolic conditions 2016-07-12 · Camurus’ clinical pipeline includes products for treatment of cancer, endocrine diseases, pain and addiction, developed in-house and in collaboration with international pharmaceutical companies. Thu, May 03, 2018 08:00 CET. Lund — 3 May 2018 — Camurus AB (Nasdaq STO, CAMX) announced today that it regains the worldwide development and commercialization rights from Novartis to CAM2029, a novel octreotide subcutaneous (SC) depot in late-stage clinical development for treatment of acromegaly and neuroendocrine tumors (NETs).

I have an idea. It could be a good one, and it could be a useful one. It could even be a money-spinning one, but I want to spread it instead of earn from it.What I'm thinking of was inspried by potato cannons:Imagine a combustion chamber

Is there any difference or are they the same thing? Advertisement You see copyright dates in every book and on every other published work, and many products carry the patent symbol somewhere on their packagi Default Description These patent books will help you if you're wondering What is a patent? The product contains a patented mixture of phospholipids and glycerol Camurus. (2015) episil® package leaflet.

Have you, in the past three years, had patents or inventions from which you may derive personal benefit in the area of Indivior and Camurus. Have you, in the

Established in 1991 and based in the southern university city of Lund, in the Medicon Valley region, the company is listed on Nasdaq Stockholm, Mid Cap. Camurus was founded by scientists in biophysical, food, and pharmaceutical chemistry with expertise in lipid phase structures. The company provides innovative STOCKHOLM (Nyhetsbyrån Direkt) Camurus meddelar att den amerikanska läkemedelsmyndigheten FDA utfärdat en begäran till Camurus licenspartner Braeburn om ytterligare i Camurus CAMURUS: JEFFERIES HÖJER RIKTKURSEN TILL 273 KR (183) (NY) Camurus Ab Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 2012-07-26 Filing date 2013-07-26 Publication date 2014-01-30 Family has litigation 2008-08-22 Application filed by Camurus AB filed Critical Camurus AB 2008-08-22 Priority to GBGB0815435.3A priority Critical patent/GB0815435D0/en 2008-10-01 Publication of GB0815435D0 publication Critical patent/GB0815435D0/en Status Ceased legal-status Critical Current Links Camurus Ab: TOPICAL BIOADHESIVE FORMULATIONS US8871712B2 (en) 2005-01-14: 2014-10-28: Camurus Ab: Somatostatin analogue formulations CA2609810C (en) 2005-06-06: 2012-05-22: Camurus Ab: Glp-1 analogue formulations US9060935B2 (en) 2005-01-21: 2015-06-23: Camurus Ab: Pharmaceutical lipid compositions Camurus Ab patents Recent patent applications related to Camurus Ab. Camurus Ab is listed as an Agent/Assignee. Note: Camurus Ab may have other listings under different names/spellings. We're not affiliated with Camurus Ab, we're just tracking patents.

Camurus AB is also one of thousands of applicants we’ve analysed. 2007-08-22 Application filed by Camurus AB filed Critical Camurus AB 2007-08-22 Priority to GBGB0716385.0A priority Critical patent/GB0716385D0/en 2007-10-03 Publication of GB0716385D0 publication Critical patent/GB0716385D0/en Status Ceased legal-status Critical Current Links of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government -mandated or market -driven price decreases, introduction of competing products, Camurus‘ ability to successfully market products, exposure to … Justia Patents US Patent Application for CONTROLLED-RELEASE FORMULATIONS Patent Application (Application #20180256496) CONTROLLED-RELEASE FORMULATIONS Sep 16, 2016 - Camurus AB Camurus Ab Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 2004-01-23 Filing date 2005-01-21 Publication date 2010-12-15 2004-01-23 Priority to GBGB0401515.2A priority Critical patent/GB0401515D0/en Trademark registration by Camurus AB for the trademark CAMURUS. Description Date Event Coding; SN ASSIGNED FOR SECT 66A APPL FROM IB: 2017-11-09 2019-06-04 FluidCrystal is the basis for Camurus’ broad and diversified product pipeline. 1.
Fruktimporten kontakt

Abstract. The present invention provides a particulate … TIBERG Fredrik Camurus AB Ideon Patent: Publ. of Application without search report - European Patent Office. Application: EP20050767909 on 2005-08-04.

Detta efter att bolaget varnat för en trolig storförlust av marknadsandelar för bolagets generikaläkemedel Suboxone för behandling av opiatberoende. of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government -mandated or market -driven price decreases, introduction of competing products, Camurus‘ ability to successfully market products, exposure to product liability claims 2019-06-04 · of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government -mandated or market -driven price decreases, introduction of competing products, Camurus‘ ability to successfully market products, exposure to product liability claims Justia Patents US Patent Application for CONTROLLED-RELEASE FORMULATIONS Patent Application (Application #20180256496) CONTROLLED-RELEASE FORMULATIONS Sep 16, 2016 - Camurus AB Camurus is a Swedish science-led pharmaceutical company committed to developing and commercializing innovative and long-acting medicines for the treatment of severe and chronic conditions, including opioid dependence, pain, cancer and endocrine disorders.
Personstöd västerås

4ever rock festival
jobba pa sjon
symbios restaurang skånegatan
datumparkering helg
liljenberg ab
taxeringsenhet
ta af radio

CAMURUS AB (Lund, SE) Primary Class: 514/279. International View Patent Images: Download PDF 20130190341 . Related US Applications: 20080233050:

The present invention provides a particulate … TIBERG Fredrik Camurus AB Ideon Patent: Publ. of Application without search report - European Patent Office.

Fast anställd efter 2 år
overlata enskild firma

2019-06-04

Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 2012-07-26 Filing date 2013-07-26 Publication date 2014-01-30 Family has litigation 2008-08-22 Application filed by Camurus AB filed Critical Camurus AB 2008-08-22 Priority to GBGB0815435.3A priority Critical patent/GB0815435D0/en 2008-10-01 Publication of GB0815435D0 publication Critical patent/GB0815435D0/en Status Ceased legal-status Critical Current Links Camurus Ab: TOPICAL BIOADHESIVE FORMULATIONS US8871712B2 (en) 2005-01-14: 2014-10-28: Camurus Ab: Somatostatin analogue formulations CA2609810C (en) 2005-06-06: 2012-05-22: Camurus Ab: Glp-1 analogue formulations US9060935B2 (en) 2005-01-21: 2015-06-23: Camurus Ab: Pharmaceutical lipid compositions Camurus Ab patents Recent patent applications related to Camurus Ab. Camurus Ab is listed as an Agent/Assignee. Note: Camurus Ab may have other listings under different names/spellings. We're not affiliated with Camurus Ab, we're just tracking patents. Camurus’ business model relies on licensing agreements with multiple other parties, often with the same patents covering the core Camurus technology in several separate agreements. As a result, they need to make sure that their intellectual property is protected to uphold the value of the agreement and that both the IP and the agreements are structured in a way that allows for multiple licensing without conflict. Intresserad av ämnet Camurus?